Sign In
Buy ABEO
$6.42
-0.0500 (-0.773%)
At Close: Jul 31, 2026
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
11:30am, Thursday, 19'th May 2022 GlobeNewswire Inc.
NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been grante
AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
07:12pm, Wednesday, 18'th May 2022 Zacks Investment Research
Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
03:47pm, Wednesday, 18'th May 2022 Zacks Investment Research
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
Philips' (PHG) Launches a Range of New Products at EuroPCR 2022
02:50pm, Tuesday, 17'th May 2022 Zacks Investment Research
Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.
AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug
01:27pm, Tuesday, 17'th May 2022 Zacks Investment Research
AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene
Abeona Therapeutics (ABEO) CEO, Vishwas Seshadri on Q1 2022 Results - Earnings Call Transcript
11:02am, Tuesday, 17'th May 2022
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Vishwas Seshadri - Chief Executive Officer Joseph Vazzano - Chief Financial Office
Abeona Therapeutics Reports First Quarter 2022 Financial Results
11:30am, Friday, 13'th May 2022 GlobeNewswire Inc.
Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023
AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals
06:47pm, Thursday, 12'th May 2022 Zacks Investment Research
AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
06:28pm, Wednesday, 11'th May 2022 Zacks Investment Research
Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates
06:36pm, Tuesday, 10'th May 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
bluebird (BLUE) Q1 Earnings and Sales Fall Short of Estimates
06:33pm, Tuesday, 10'th May 2022 Zacks Investment Research
bluebird's (BLUE) Q1 loss is worse than expected while sales lag estimates. It retains its dialogue with the FDA to resolve the clinical hold issue over its pipeline.
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
03:37pm, Tuesday, 10'th May 2022 Zacks Investment Research
Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.
Intercept (ICPT) Q1 Earnings Top, Ocaliva Sales Miss Estimates
06:42pm, Monday, 09'th May 2022 Zacks Investment Research
Intercept (ICPT) posts a narrower-than-expected loss in the first quarter. Sales lag estimates.
Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
07:48pm, Friday, 06'th May 2022 Zacks Investment Research
Aerie (AERI) misses on both earnings and revenues for the first quarter of 2022.
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
07:38pm, Friday, 06'th May 2022 Zacks Investment Research
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
